Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2021-07, Vol.65 (8), p.e0048621-e0048621
Hauptverfasser: Bhatnagar, Amelia, Boyd, Sandra, Sabour, Sarah, Bodnar, Janine, Nazarian, Elizabeth, Peinovich, Nadine, Wagner, Christine, Craft, Bradley, Snippes Vagnone, Paula, Simpson, Justin, Stone, Victoria N, Therrien, Michelle, Bateman, Allen, Lower, Danielle, Huang, Jennifer Y, Gumbis, Stephanie, Lonsway, David, Lutgring, Joseph D, Karlsson, Maria, Brown, Allison C
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Azabicyclo Compounds - pharmacology
Aztreonam - pharmacology
beta-Lactamases - genetics
Ceftazidime
Drug Combinations
Drug Resistance, Microbial
Humans
Laboratories
Microbial Sensitivity Tests
Susceptibility
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC and MIC values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent activity against the MBL-producing tested.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00486-21